Business Wire

ADVA

5.5.2020 09:02:06 CEST | Business Wire | Press release

Share
FUNET trials ADVA FSP 3000 TeraFlex™ to dramatically expand network capacity

ADVA (FSE: ADV) today announced that CSC – IT Center for Science, which operates the Finnish University and Research Network (FUNET), has transported 400Gbit/s over its existing long-haul network using the ADVA FSP 3000 TeraFlex™ . The trials pave the way for ultra-fast access to Finland’s supercomputers and could offer a major boost to Europe’s research and education community. They also demonstrated the terminal’s ability to carry 1200Gbit/s channels for the transport of 3x 400GbE over a live meshed ROADM infrastructure. What’s more, the trials highlighted how TeraFlex™ maximizes spectral efficiency in any open line system. Using the terminal’s ultra-flexible modulation and adaptive baud rate capabilities, FUNET also achieved new levels of bandwidth efficiency – and therefore could significantly reduce opex – for 400GbE, 100GbE and lower-speed services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005036/en/

“These trials demonstrate how the ADVA FSP 3000 TeraFlex™ performs over long-haul distances, and the results were well above our expectations. It was the first time when we really needed a gridless line system to enable a full choice of line speeds and modulations. The powerful performance of TeraFlex™ and its flexibility to tune line speed and modulation, will allow us to optimize spectrum usage and minimize the cost of providing services to our users,” said Jani Myyry, FUNET network, CSC – IT Center for Science. “Our network provides essential connectivity for research and education institutes in Finland and throughout the Nordics. Initially we were aiming for transport based on 100Gbit/s and 200Gbit/s but are now seeing an increasing need for speeds above that, up to use cases requiring a bandwidth of multiple Tbit/s. TeraFlex and our ADVA open line system infrastructure enable us to efficiently scale our network with line speeds of 400Gbit/s and above. The trials show how TeraFlex™ dramatically increases flexibility and efficiency for 100GbE and 400GbE transport over long-haul distances.”

FUNET’s tests underline the ability of the ADVA FSP 3000 TeraFlex™ to massively increase the capacity of existing terrestrial long-haul networks. The low-power 1RU terminal enables channels of up to 1200Gbit/s for 3x 400GbE services and a total capacity of 3.6Tbit/s. Using network telemetry, software-defined fractional QAM modulation and adaptive baud rate capabilities, the solution is able to ensure maximum spectral efficiency at every point in the network. This enables operators to leverage previously unused optical spectrum so that deployed infrastructure can be made to transport far more data. As well as succeeding with 600Gbit/s transport over 278km and with 400Gbit/s over 2,844km, the trials showed the power of harnessing granular increments with speeds of 300Gbit/s over 4,681km.

“These tests show how it’s now possible to optimize all optical paths over any reach. They demonstrate to the research and education industry that there’s a new way for long-distance networks to support soaring data demand. With its ultra-flexible modulation, our compact and open FSP 3000 TeraFlex™ is the key to unlocking maximum value in any network,” commented Henning Hinderthür, VP, product line management, ADVA. “Together with the CSC – IT Center for Science, we’ve shown how deployed infrastructure operating with coherent channels can transport traffic at unprecedented speeds. And not only that. Our unique TeraFlex™ solution also enhances performance, improves port efficiency and delivers major opex savings. It massively increases the efficiency of existing 100GbE connectivity, while also providing a way to meet the needs of emerging data-hungry applications for 400GbE and beyond.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com .

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye